Skip to main content

Table 1 Baseline characteristics of study participants and comparisons between cases and controls. Data are presented for the study cohort, categorised in to cases and controls, for mean deprivation score, numbers of self-reported comorbidities, and WHO BMI categories. Tests of statistical differences were applied

From: The Enhanced Liver Fibrosis test is associated with liver-related outcomes in postmenopausal women with risk factors for liver disease

Characteristic

Cases

Controls

All participants

p value†

Participants, n

58

115‡

173

 

Age at recruitment, median (range)

60.9 (51.6–74.3)

61.5 (51.8–74.2)

61.0 (51.8–74.3)

0.8501a,d

IMD, mean (SD)

25.55 (17.03)

19.86 (15.61)

21.8 (16.3)

0.031a

Hypertension, n (%)

26 (44.8)

39 (33.9)

65 (37.6)

0.162b

Heart disease, n (%)

8 (13.8)

13 (11.3)

21 (12.1)

0.636b

Hypercholesterolaemia, n (%)

22 (37.9)

32 (27.8)

54 (31.2)

0.176b

Type 2 diabetes, n (%)

11 (19.0)

5 (4.3)

16 (3.4)

0.002b

Smoker, n (%)e

33 (57)

38 (33) 13 missing

71 (44.4) 13 missing

0.016b

Stroke, n (%)

1 (1.7)

0 (0.0)

1 (0.6)

0.335c

BMI

(kg/m2)

n, (%)

< 25

7 (12.1)

15 (13.0)

22 (12.7)

0.856a,d

25 - < 30

33 (56.9)

65 (56.5)

98 (56.6)

0.963a,d

≥30

18 (31.0)

35 (30.4)

53 (30.6)

0.936a,d

Alcohol

(units/week)

n, (%)

None

18 (31.0)

35 (30.4)

53 (30.6)

0.936a,d

< 1–10

29 (50.0)

58 (50.4)

87 (50.3)

0.957a,d

11–15

7 (12.1)

14 (12.2)

21 (12.1)

0.984a,d

16–20

2 (3.4)

4 (3.5)

6 (3.5)

0.992a,d

≥21

2 (3.4)

4 (3.5)

6 (3.5)

0.992a,d

  1. WHO World Health Organization, BMI body mass index, IMD Index of Multiple Deprivation
  2. † at the 5% level. ‡ One control excluded as per UKCTOCS protocol
  3. a Independent sample t-test; bPearson’s Chi-square test; c Fisher’s exact test; d Matched variable; e variable excluded from regression analyses